Literature DB >> 20118799

Analysis of propofol/remifentanil infusion protocol for tumor surgery with intraoperative brain mapping.

Valeria Conte1, Lorenzo Magni, Valeria Songa, Paola Tomaselli, Laura Ghisoni, Sandra Magnoni, Lorenzo Bello, Nino Stocchetti.   

Abstract

BACKGROUND: There is no general consensus about the best anesthesiologic approach to use during craniotomies with intraoperative brain mapping, and large prospective studies evaluating the complications associated with different approaches are lacking. Objective of this study was to prospectively collect and evaluate data about a large series of consecutive asleep-awake and asleep-asleep craniotomies.
METHODS: We analyzed 238 consecutive procedures from January 2005 to December 2008. During asleep-awake procedures, patients were initially ventilated through a laryngeal mask which was removed to allow language testing. During asleep-asleep procedures, patients remained sedated and intubated to permit motor testing.
RESULTS: In asleep-awake craniotomies [n=135, age 42 y (range: 16 to 72 y), American Society of Anesthesiologists classification (ASA) 1 (1 to 3), and body mass index 24.2+/-3.7 kg/m], 43% of the procedures were free of complications. Most common complications were hypertension (27%) and brief clinical seizures (16%), but also hypotension (10%), vomiting (7%), brief periods of apnea (4%), and agitation (6%) were observed. In 7% of the procedures, seizures required pharmacologic treatment. Fifty-nine percent of the asleep-asleep procedures [n=103, age 51 y (range: 21 to 76 y), ASA 1 (1 to 3), body mass index 25.4+/-3.9 kg/m, P<0.05 vs. asleep-awake] were free of complications. Clinical seizures were observed in 31% of the cases. The administration of boluses of hypnotics was rarely necessary (6%) and safer because of secured airways.
CONCLUSIONS: With this study, we demonstrated the feasibility and safety of our protocols on large prospective case series. Asleep-awake protocol can be safely used when intraoperative language mapping is planned, whereas an asleep-asleep protocol with secured airway might be preferred when motor testing only is required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118799     DOI: 10.1097/ANA.0b013e3181c959f4

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

Review 1.  Maximizing safe resection of low- and high-grade glioma.

Authors:  Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  J Neurooncol       Date:  2016-05-12       Impact factor: 4.130

2.  Risk of seizures during intraoperative electrocortical stimulation of brain motor areas: a retrospective study on 50 patients.

Authors:  Roberto Cordella; Francesco Acerbi; Carlo Efisio Marras; Carla Carozzi; Davide Vailati; Marco Saini; Giovanni Tringali; Paolo Ferroli; Francesco Dimeco; Angelo Franzini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2012-02-17       Impact factor: 3.307

3.  The effect of single low-dose dexamethasone on vomiting during awake craniotomy.

Authors:  Kotoe Kamata; Nobutada Morioka; Takashi Maruyama; Noriaki Komayama; Masayuki Nitta; Yoshihiro Muragaki; Takakazu Kawamata; Makoto Ozaki
Journal:  J Anesth       Date:  2016-08-29       Impact factor: 2.078

4.  Characteristic Alterations of Network in Patients With Intraoperative Stimulation-Induced Seizures During Awake Craniotomy.

Authors:  Shengyu Fang; Chunyao Zhou; Lei Wang; Xing Fan; Yinyan Wang; Zhong Zhang; Tao Jiang
Journal:  Front Neurol       Date:  2021-03-18       Impact factor: 4.003

5.  Diffusion tensor imaging, intra-operative neurophysiological monitoring and small craniotomy: Results in a consecutive series of 103 gliomas.

Authors:  Giorgio Carrabba; Giorgio Fiore; Andrea Di Cristofori; Cristina Bana; Linda Borellini; Barbara Zarino; Giorgio Conte; Fabio Triulzi; Alessandra Rocca; Carlo Giussani; Manuela Caroli; Marco Locatelli; Giulio Bertani
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

6.  Awake craniotomy for tumor resection.

Authors:  Mohammadali Attari; Sohrab Salimi
Journal:  Adv Biomed Res       Date:  2013-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.